Skip to content
OpenCapital
Get started

Kymera Therapeutics KYMR Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$2.8MMiss by $11.7M
EPS-$0.90Miss by $0.19
Revenue estimate$14.5M
EPS estimate-$0.71

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$32.2M
EPS estimate-$0.72

Financials

Q3 2025

Income statement

See full
Revenue$2.8M-26.1%
Operating income-$92.5M-28.3%
Net income-$82.2M-31.5%
EPS (diluted)-$0.94-14.6%

Balance sheet

See full
Cash & equivalents$112.9M+2.0%
Total debt$85.9M-4.1%
Total equity$946.3M+6.0%
Total assets$1.1B+6.5%

Cash flow

See full
Operating cash flow-$27.1M+46.0%
CapEx$181.0K—
Free cash flow-$27.3M+45.4%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$4.05B+12.3%
Enterprise value$4.02B+12.2%
P/S92.5×+51.4×

Profitability

See full
Operating margin-759.7%-1,334pp
Net margin-674.8%-1,116pp
FCF margin-526.4%-1,001pp

Returns & leverage

See full
Return on equity-32.1%+9.8pp
Debt / equity0.1×0.0×
Current ratio7.4×-1.2×

Versus estimates

Revenue

Q1 2026$34.4MBeat by $26.1MQ4 2025$2.9MMiss by $12.2M
Q3 2025$2.8MMiss by $11.7M
Q2 2025$11.5MMiss by $5.7MQ1 2025$22.1MBeat by $9.7MQ4 2024$7.4MMiss by $9.3M

Diluted EPS

Q1 2026-$0.71Beat by $0.18Q4 2025-$0.97Miss by $0.19
Q3 2025-$0.90Miss by $0.19
Q2 2025-$0.95Miss by $0.12Q1 2025-$0.82Beat by $0.10Q4 2024-$0.88Miss by $0.12

Ask the moment Kymera Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Kymera Therapeutics report Q3 2025 earnings?
Kymera Therapeutics (KYMR) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Kymera Therapeutics's Q3 2025 revenue and EPS?
Kymera Therapeutics reported revenue of $2.8M and eps of $-0.90 for Q3 2025.
Did Kymera Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $14.5M by $11.7M. EPS missed the consensus estimate of $-0.71 by $0.19.
How did Kymera Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 26.1% from $3.7M a year earlier and eps declined 9.8% from $-0.82.
Where can I find Kymera Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-263540) and the 10-Q periodic report (0001193125-25-263550) directly on SEC EDGAR. The filing index links above go to sec.gov.